In symptomatic HF, sacubitril–valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo

Q: What does this research mean for the field?

In symptomatic heart failure, treatment with sacubitril-valsartan versus dapagliflozin, and torsemide versus furosemide, results in no significant difference in health status at 6 months. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Daniel Steinberg

doi:10.7326/annals-26-02647-jc

August 3, 2026Annals of Internal Medicine

In symptomatic HF, sacubitril–valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo

View at Publisher

Ask AI

Bookmark

Share

Key Points

To compare the effects of sacubitril–valsartan and dapagliflozin on health status in symptomatic heart failure patients.
Randomized controlled trial
Evaluated health status at 6 months
Compared treatment groups: sacubitril–valsartan vs. dapagliflozin and torsemide vs. furosemide.
No significant difference in health status between sacubitril–valsartan and dapagliflozin at 6 months.
No significant difference in health status between torsemide and furosemide at 6 months.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Compares health status effects of sacubitril–valsartan and dapagliflozin in heart failure, indicating similar outcomes.

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Daniel Steinberg (2026) studied this question.

synapsesocial.com/papers/6a743706764cddc9499d456a https://doi.org/10.7326/annals-26-02647-jc

View at Publisher

Ask AI

Bookmark

Share

In symptomatic HF, sacubitril–valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

In symptomatic HF, sacubitril–valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading